Jun 23, 2025, 12:40
A New Era in Hemophilia A Prophylaxis: Dr. Shima Presented Groundbreaking Phase I/II Results for NXT007
NXT007 Hemophilia A Prophylaxis took center stage today when Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared a post on X.
“A New Era in Haemophilia A Prophylaxis. Dr. Shima presented groundbreaking phase I/II results for NXT007, a next-generation bispecific antibody: 30 patients with severe haemophilia A (no inhibitors), age range: 12-65 years (median age 39.5 years), subcutaneous dosing: 0.072-1.08 mg/kg every 4 weeks.
Higher dose cohorts (B-3, B-4) achieved FVIII-equivalent activity in the normal range.
Well-tolerated profile with no thromboembolic events, but high anti-drug antibody prevalence: 22/30 patients (73%) and effect on plasma concentrations in 2/22.”
Stay up to date with Hemostasis Today
-
Apr 11, 2026, 13:51David McIntosh: Vital Plasma Derived Medicines – The Anomalous UK Scene
-
Apr 11, 2026, 13:47Samrawit Terefe: O Negative Blood Is the Universal Donor With Extreme Scarcity
-
Apr 11, 2026, 13:39Dheeraj Garg: Rethinking Cardiovascular Disease – A Cardiologist’s Perspective
-
Apr 11, 2026, 13:37Kushal Bhatia: Is The 4.5-Hour Thrombolysis Window Officially Outdated?
-
Apr 11, 2026, 13:35William Aird: Why Did Mammalian Red Blood Cells Give Up Their Nucleus?
-
Apr 11, 2026, 13:30Ken Kuang: Gravity Is Constant, But Your Vein Health Doesn’t Have to Be
-
Apr 11, 2026, 13:21Mascha Kern: Measuring Gender’s Role in Stroke and Migraine
-
Apr 11, 2026, 13:10Danique Steeghs: Key Findings from a Microfluidic Chemiluminescent Thrombin Generation Assay
-
Apr 11, 2026, 13:06Shanvi Mahi: A Validated Tool to Explore Lived Experiences After Stroke Rehabilitation